SCHEMBL18656597

SCHEMBL18656597

C[C@H](CC(C)(C)[Si](O)(c1ccccc1)c1ccccc1)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
APAF1 O14727 5/20 0.39
ALDH1A1 P00352 1/20 0.38
POLB P06746 2/20 0.37
RXRA P19793 1/20 0.35
NR4A2 P43354 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
RECQL P46063 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MME P08473 5/20 0.34
ACE P12821 4/20 0.34
KIF11 P52732 1/20 0.33
TBXAS1 P24557 1/20 0.33
ELANE P08246 1/20 0.33
CYP2C19 P33261 1/20 0.33
HIF1A Q16665 1/20 0.33
MMEL1 Q495T6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15452092 1.00 APAF1 (0.39) APAF1ALDH1A1POLBRXRANR4A2
SCHEMBL19273823 1.00 APAF1 (0.39) APAF1ALDH1A1POLBRXRANR4A2
SCHEMBL19274004 0.87 NPC1 (0.33) APAF1ALDH1A1POLBMAPTCYP2C19
SCHEMBL19273972 0.87 NPC1 (0.33) APAF1ALDH1A1POLBMAPTCYP2C19
SCHEMBL14948713 0.84 ESRRB (0.43) ALDH1A1POLBMAPTL3MBTL1CYP2C19
SCHEMBL19545536 0.84 APAF1 (0.37) APAF1ALDH1A1POLBKIF11
SCHEMBL15886149 0.82 GAA (0.36) ALDH1A1KIF11CYP2C19
SCHEMBL18656603 0.81 ALDH1A1 (0.44) ALDH1A1POLBMAPTL3MBTL1
SCHEMBL8365065 0.81 CYP1A2 (0.32) ALDH1A1CYP2C19
SCHEMBL13785363 0.81 CYP1A2 (0.41) ALDH1A1NR4A2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9808531-B2 Compounds and compositions for the treatment of ocular disorders Graybug Vision, Inc. (US) 2017-11-07 US disclosed
US-20170080092-A1 Compounds And Compositions for the Treatment of Ocular Disorders Graybug Vision, Inc. (US) 2017-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170080092-A1 Compounds And Compositions for the Treatment of Ocular Disorders PTGIR, PTGIS, CA2 APAF1 3487/4885ALDH1A1 1010/4885POLB 3189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.